Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy

Purpose: Women with advanced epithelial ovarian cancer are routinely treated with platinum-paclitaxel chemotherapy following cytoreductive surgery, yet only ∼20% achieve long-term disease-free survival. We hypothesized that differences in gene expression before treatment could distinguish patients with short versus long time to recurrence after administration of platinum-paclitaxel combination chemotherapy. Experimental Design: To test this hypothesis, gene expression profiling of 79 primary surgically resected tumors from women with advanced-stage, high-grade epithelial ovarian cancer was done using cDNA microarrays containing 30,721 genes. Supervised learning algorithms were applied in an effort to develop a binary classifier that could discriminate women at risk for early (≤21 months) versus late (>21 months) relapse after initial chemotherapy. Results: A 14-gene predictive model was developed using a set of training samples (n = 51) and subsequently tested using an independent set of test samples (n = 28). This model correctly predicted the outcome of 24 of the 28 test samples (86% accuracy) with 95% positive predictive value for early relapse. Conclusions: Predictive markers for early recurrence can be identified for platinum-paclitaxel combination chemotherapy in primary ovarian carcinoma. The proposed 14-gene model requires further validation.

[1]  E. Lander,et al.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Trevor Hastie,et al.  Gene expression patterns in ovarian carcinomas. , 2003, Molecular biology of the cell.

[3]  Bernd Bohnet,et al.  Expression analysis of protein kinase C isozymes and multidrug resistance associated genes in ovarian cancer cells. , 1998, Anticancer research.

[4]  G. Mills,et al.  Genetic analysis of early- versus late-stage ovarian tumors. , 2001, Cancer research.

[5]  Kathleen R. Cho,et al.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.

[6]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[7]  M. King,et al.  BRCA1 transcriptionally regulates genes involved in breast tumorigenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Michael P Heldebrant,et al.  Phorbol 12-myristate 13-Acetate Inhibits Death Receptor-mediated Apoptosis in Jurkat Cells by Disrupting Recruitment of Fas-associated Polypeptide with Death Domain* , 2002, The Journal of Biological Chemistry.

[9]  Jeffrey R Marks,et al.  Gene Expression Patterns That Characterize Advanced Stage Serous Ovarian Cancers , 2004, The Journal of the Society for Gynecologic Investigation: JSGI.

[10]  D. Lockhart,et al.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  S. Mok,et al.  Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. , 2001, BioTechniques.

[12]  Tsutomu Ohta,et al.  Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. , 2003, The American journal of pathology.

[13]  C. Perez,et al.  Principles and Practice of Gynecologic Oncology , 1992 .

[14]  S. Kaye,et al.  Protein kinase C inhibitors , 2002, Current oncology reports.

[15]  S. Cannistra.  Medical progress : cancer of the ovary , 1993 .

[16]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[17]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, New England Journal of Medicine.

[18]  M. Morgan,et al.  Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. , 1996, The New England journal of medicine.

[19]  Kazuhiro Takahashi,et al.  Inhibition of NFκB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models* , 2004, Journal of Biological Chemistry.

[20]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[21]  L. Staudt,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[22]  P. J. Welch,et al.  Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Boyd,et al.  Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. , 2000, JAMA.

[24]  G. Murphy,et al.  American Joint Committee on Cancer prognostic factors consensus conference. , 1999, Cancer.

[25]  R. Ozols,et al.  Focus on epithelial ovarian cancer. , 2004, Cancer cell.

[26]  Christos Sotiriou,et al.  Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. , 2002, Journal of the National Cancer Institute.

[27]  Cheng Cheng,et al.  Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.

[28]  J. Stec,et al.  Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Chris Cheadle,et al.  Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. , 2002, Cancer research.

[30]  B N Bundy,et al.  Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. L. Baldwin,et al.  Gene expression in epithelial ovarian carcinoma , 2002, Oncogene.

[33]  S. Sugano,et al.  Large-scale identification and characterization of human genes that activate NF-κB and MAPK signaling pathways , 2003, Oncogene.

[34]  C. Tropé,et al.  The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. , 1995, Gynecologic oncology.

[35]  T. Golub,et al.  DNA microarrays in clinical oncology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Laurence Ettwiller,et al.  An orchestrated gene expression component of neuronal programmed cell death revealed by cDNA array analysis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[37]  P. Bader,et al.  Induction of drug resistance and protein kinase C genes in A2780 ovarian cancer cells after incubation with antineoplastic agents at sublethal concentrations. , 2002, Anticancer research.

[38]  M. McKay,et al.  Cancer of the ovary. , 1994, The New England journal of medicine.

[39]  T Tanaka,et al.  Identification by cDNA microarray of genes involved in ovarian carcinogenesis. , 2000, Cancer research.

[40]  Tim Hui-Ming Huang,et al.  Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  Roger E Bumgarner,et al.  Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. , 1999, Gene.

[42]  E. Venkatraman,et al.  Identification of prognostic factors in advanced epithelial ovarian carcinoma. , 2001, Gynecologic oncology.

[43]  L. Hartmann,et al.  Prognostic significance of p53 immunostaining in epithelial ovarian cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  M. Radmacher,et al.  Design of studies using DNA microarrays , 2002, Genetic epidemiology.

[45]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Stec,et al.  Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.